posted
Global General Technologies Inc. (GLGT) Finalizes Merger with AB (Wuhan) Biotech
Press Release Source: Global General Technologies Inc. On Thursday April 21, 2011, 3:45 pm EDT HENDERSON, NEVADA--(Marketwire - 04/21/11) - Global General Technologies Inc. (PINK SHEETS:GLGT - News)(Welcome To Global General Technologoes) is pleased to announce the completion of its merger with Wuhan, China-based biotech company AB (Wuhan) Biotech Co. Ltd. GLGT introduced AB (Wuhan) Biotech as its merger candidate at the end of March. AB (Wuhan) Biotech is a China-based entity with ties to the American market (Abgenom, American Centrality Croup, Inc.). The company focuses on research and development, production and marketing mainly for Chinese market. Its principal objective is to become a leading supplier in molecular diagnosis and home-applicable end-user In Vitro Diagnostic (IVD) markets. The ultimate goal is to be the leader in developing and producing high quality, cutting-edge diagnostic products for various human diseases. AB (Wuhan) Biotech is committed to developing, commercializing and popularizing advanced IVD kits/devices to improve human health. Its primary business is to design, develop, patent and market home-applicable diagnostic test papers and portable diagnostic devices related to cardiovascular diseases. GLGT and AB Wuhan Biotech will soon update investors and followers of additional developments, including revenues, assets and merger details (including new management), through a separate filing and/or a news release.
Posts: 119 | From: new york | Registered: Sep 2009
| IP: Logged |
posted
Global General Technologies Inc. (GLGT) Reveals 2010 Revenues and Profits
Press Release Source: Global General Technologies Inc. On Monday April 25, 2011, 3:45 pm HENDERSON, NEVADA--(Marketwire - 04/25/11) - Global General Technologies Inc. (PINK SHEETS:GLGT - News) (www.glgt-corporate.com) and its main subsidiary, AB (Wuhan) Biotech Co. Ltd., have revealed the company's revenues and profits for 2010.
AB (Wuhan) Biotech boasted revenues of $1,840,354.92 U.S. and profits of $360,776.48 U.S. in 2010. GLGT recently acquired AB (Wuhan) Biotech, a Wuhan, China-based biotech company that's committed to developing, commercializing and popularizing advanced In Vitro Diagnostic (IVD) kits/devices.
GLGT and AB (Wuhan) Biotech release this information to show the true value brought to GLGT by the merger with its new subsidiary. GLGT management is pleased with these financial results and feels that, following a long period of silence, company followers deserve to see as much information as possible.
UBBFriend: Email this page to someone!
Printer-friendly view of this topic
